JTJulia Tchou

Julia Tchou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julia Tchou has a total of 230 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Distinct Mitochondrial Recovery Dynamics Following Taxol Removal in Triple-Negative Breast Cancer Cells

    by Jack Kollmar, Mihiar Wannousse, Julia Tchou, Lin Z. Li, He N. Xu

    Drug resistance in TNBC is associated with metabolic plasticity, yet little is known about how mitochondrial and cellular states evolve after chemotherapeutic withdrawal. We used optical redox imaging (ORI) microscopy and complementary functional measurements to characterize post-Taxol recovery in two TNBC cell lines with different Taxol sensitivities. Whole-dish nuclear counting following 48 h Taxol treatment confirmed that HCC1806 cells responded at lower Taxol concentrations than MDA-MB-436 cells. Recovery was subsequently monitored following extracellular Taxol withdrawal using mitochondrial redox indices, mitochondrial reactive oxygen species (mito-ROS), mitochondrial membrane potential (MMP), multinucleation, and live- and dead-cell counts. HCC1806 cells showed substantial recovery of several mitochondrial parameters and resolution of multinucleation by 96 h; however, a late reductive shift in the optical redox ratio (ORR), reduced MMP, and attenuated live-cell population expansion indicated incomplete redox and functional recovery. In contrast, MDA-MB-436 cells exhibited persistent elevations in Fp and ORR through 144 h, residual multinucleation, and little sustained live-cell population expansion. These findings demonstrate that mitochondrial, multinucleation, and population-level recovery can proceed on different timescales and that post-treatment recovery differs markedly between TNBC models with different Taxol sensitivities. Longitudinal ORI provides a non-destructive approach for characterizing persistent post-treatment metabolic states and, together with functional measurements, may facilitate investigation of recovery-associated phenotypes relevant to therapeutic response.

  • Open Access

    Live-Cell Optical Redox Imaging Reveals Metabolic Heterogeneity and Context-Dependent Responses to Metabolic Perturbation in TNBC Cells

    by He N. Xu, Jack Kollmar, Allison Podsednik, Mihiar Wannousse, Alexander Shestov, Roddy S. O’Connor, Joseph A. Baur, Julia Tchou, Rong Zhou, Lin Z. Li

    Background/Objectives: Triple-negative breast cancer (TNBC) exhibits substantial metabolic heterogeneity and plasticity, contributing to variable therapeutic responses. We investigated whether optical redox imaging (ORI) could characterize metabolic phenotypes, monitor responses to metabolic perturbation, and relate these responses to functional outcomes in TNBC cells. Methods: Four TNBC cell lines were treated with the lactate dehydrogenase A inhibitor FX11 or the glutaminase inhibitor CB-839, alone or in combination with paclitaxel. Intensity-based label-free ORI was performed and followed by imaging of fluorescent probes to assess mitochondrial membrane potential (MMP), re-active oxygen species (ROS), and cell number in the same dishes. Seahorse assays were used to evaluate mitochondrial respiration and glycolytic flux. Results: TNBC cell lines exhibited distinct basal redox phenotypes and differential responses to acute glycolytic and glutaminolytic perturbation. HCC1806 cells showed the strongest acute ORI responses to both FX11 and CB-839. Acute FX11 treatment induced a rapid reductive shift accompanied by ROS accumulation and loss of MMP, whereas CB-839 produced a more modest early reductive response without detectable ROS accumulation or MMP loss. Prolonged treatment revealed distinct temporal redox trajectories in HCC1806 cells: FX11-treated cells evolved from an acute reductive response toward a more oxidized state, while CB-839-treated cells transitioned from an early reductive shift to a sustained oxidized redox state accompanied by marked reductions in OCR and ECAR. Functionally, in two representative models (HCC1806 and MDA-MB-231), CB-839 reduced cell numbers and enhanced the anti-proliferative effect of paclitaxel, whereas FX11 had no significant effect on cell number despite inducing pronounced acute redox perturbations. Conclusions: Integrating ORI with metabolic flux assays and imaging-based functional measurements enables characterization of multiple dimensions of metabolic behavior, including basal phenotype, pathway-specific responsiveness, temporal redox responses, and treatment-associated outcomes. These findings support intensity-based wide-field ORI as a practical and accessible tool for probing metabolic heterogeneity and characterizing context-dependent metabolic responses in TNBC cells.


  • Open Access

    Enhanced antitumor efficacy through combined chimeric antigen receptor T cell therapy and CD40 stimulation in syngeneic solid tumor models

    by Giulia Golinelli, Ting-Jia Fan, Khatuna Gabunia, Wesley V. Wilson, Charles-Antoine Assenmacher, He N. Xu, Diego Gonzalves, Sofia Castelli, Jordan Reff, David Mai, et al.

  • Open Access

    A community based participatory research approach to evaluate barriers and facilitators for behavioral weight loss intervention implementation in a predominantly black community

    by Elizabeth De Jesus, Sean Woo, Robert S. Krouse, Carmen E. Guerra, Katharine A. Rendle, Tamara Cadet, Kelly C. Allison, Julia Tchou

    Purpose: Breast cancer survivors with overweight or obesity have worse breast cancer specific survival and outcomes as compared to those with average weight by Yung and Ligibel (Clin Adv Hematol Oncol 14:790–797, 2016) and Druesne-Pecollo et al. (Breast Cancer Res Treat 135:647–654, 2012). Our pilot Group-bas E d T elehealth behavioral We ight L os (GET-WEL) Program showed that fewer Black breast cancer survivors (BBCS) enrolled and lost less weight than White breast cancer survivors by Allison et al. (Obesity Science and Practice 10:e70023, 2024). This study is aimed at using a community-based participatory research approach to assess barriers and facilitators of implementing a behavioral weight loss intervention among BBCS. Methods: Eight BBCS from a predominantly Black community were invited to participate in semi-structured interviews that were voice recorded, transcribed, coded, and analyzed via comparative thematic analysis. Results: Thematic analyses revealed multiple barriers within participants. These included lack of affordable healthy food access, safety concerns with regards to outdoor activities, lack of affordable fitness center memberships, time constraints related to competing work/life obligations, and steep learning curves with technology use. Most BBCS preferred an integrated community-based coach to guide their weight loss interventions via a combination of both virtual and in-person sessions. Conclusion: Our results indicate that a multimodal approach including nutrition education, reducing physical activity barriers, limiting time constraints by implementing both in-person and virtual platforms, and assisting with technology courses, is necessary to improve the equitable implementation of weight loss interventions. BBCS recommended utilizing established community facilities and leveraging known community members such as nutrition counselors and physical trainers to increase successful implementation.

  • Open Access

    Differential Mitochondrial Redox Responses to the Inhibition of NAD+ Salvage Pathway of Triple Negative Breast Cancer Cells

    by Jack Kollmar, Junmei Xu, Diego Gonzalves, Joseph A. Baur, Lin Z. Li, Julia Tchou, He N. Xu

    Background/Objectives: Cancer cells rely on metabolic reprogramming that is supported by altered mitochondrial redox status and an increased demand for NAD+. Over expression of Nampt, the rate-limiting enzyme of the NAD+ biosynthesis salvage pathway, is common in breast cancer cells, and more so in triple negative breast cancer (TNBC) cells. Targeting the salvage pathway has been pursued for cancer therapy. However, TNBC cells have heterogeneous responses to Nampt inhibition, which contributes to the diverse outcomes. There is a lack of imaging biomarkers to differentiate among TNBC cells under metabolic stress and identify which are responsive. We aimed to characterize and differentiate among a panel of TNBC cell lines under NAD-deficient stress and identify which subtypes are more dependent on the NAD salvage pathway. Methods: Optical redox imaging (ORI), a label-free live cell imaging microscopy technique was utilized to acquire intrinsic fluorescence intensities of NADH and FAD-containing flavoproteins (Fp) thus the mitochondrial redox ratio Fp/(NADH + Fp) in a panel of TNBC cell lines. Various fluorescence probes were then added to the cultures to image the mitochondrial ROS, mitochondrial membrane potential, mitochondrial mass, and cell number. Results: Various TNBC subtypes are sensitive to Nampt inhibition in a dose- and time-dependent manner, they have differential mitochondrial redox responses; furthermore, the mitochondrial redox indices linearly correlated with mitochondrial ROS induced by various doses of a Nampt inhibitor. Moreover, the changes in the redox indices correlated with growth inhibition. Additionally, the redox state was found fully recovered after removing the Nampt inhibitor. Conclusions: This study supports the utility of ORI in rapid metabolic phenotyping of TNBC cells under NAD-deficient stress to identify responsive cells and biomarkers of treatment response, facilitating combination therapy strategies.


  • Open Access

    The Group‐basEd Telehealth behavioral WEight Loss Program Among Breast Cancer Survivors: A Pilot and Feasibility Study

    by Kelly C. Allison, Courtney McCuen‐Wurst, Allie Raevsky, Nathaniel Holmes, Macy Goldbach, Carmen E. Guerra, Katharine A. Rendle, Tamara J. Cadet, Robert S. Krouse, Julia Tchou

    Objective: Obesity is related to the recurrence of breast cancer. In‐person groups or individual telephone counseling currently comprise the behavioral weight loss (BWL) programs tested for cancer survivors. Group support via telehealth may be convenient and provide support from fellow survivors, but feasibility, acceptability, and efficacy testing are needed.Methods: A single‐arm, 6‐month BWL program was conducted for female breast cancer survivors with an ECOG performance 0 or 1, BMI > 25 kg/m2, and > 6 months from completion of adjuvant chemotherapy and/or radiation treatment. Participants attended 22 video group sessions over 6 months, completing acceptability ratings, weight measurements, Patient Health Questionnaire (PHQ‐9), City of Hope Breast Cancer Quality of Life Scale (QOL), and International Physical Activity Questionnaire. Changes in survey scores and weight (last‐observation carried forward) and differences in outcomes by patients' race were computed with paired t‐tests, ANCOVAs and Chi‐square tests.Results: Twenty‐one (5 Black, 15 White, 1 Asian American; Mean (SD) = 60.7 (11.6) years; BMI 33.1 (5.9) kg/m2) survivors enrolled with 90% retention and 81.3% of sessions attended. Acceptability ratings were high (all > 4 on a five‐point scale). Mean (SD) weight loss was 5.9% (5.2%), with 60% losing ≥ 5% of baseline weight; White participants lost 7.5% and Black participants lost 1.9% (p = 0.04). Significant improvements were observed in mood (PHQ‐9; p = 0.01) and physical wellbeing QOL (p = 0.01). Physical activity did not change.Conclusion: This telehealth group BWL program was feasible and acceptable for breast cancer survivors, yielding a clinically significant weight loss. Future studies should test this intervention in larger, more diverse samples.Trail Registration: ClinicalTrials.gov identifier: NCT04855552, posted April 22, 2021


  • Open Access

    Perceptions, facilitators, and barriers of participation for a behavioral weight loss group-based telehealth program for breast cancer survivors: a qualitative study

    by Yangzi Liu, Elizabeth De Jesus, Macy Goldbach, Robert S. Krouse, Carmen E. Guerra, Katharine A. Rendle, Tamara J. Cadet, Kelly C. Allison, Julia Tchou

    Purpose: Results from the pilot Group-basEd Telehealth behavioral Weight Loss (GET-WEL) Program (NCT04855552) showed that fewer Black breast cancer survivors (BCS) enrolled than White BCS. Black participants also lost less weight than White participants. Little is known about mitigating factors or how best to implement such programs equitably. In this study, we explored facilitators and barriers in Black and White BCS who did or did not participate in GET-WEL. Methods: BCS who are overweight or obese (body mass index (BMI) ≥ 25 kg/m2) and who had previously been assessed for their willingness to participate in GET-WEL were invited to participate in a semi-structured telephone interview conducted from June to August 2023. Interviewees were purposefully sampled from those who did (participants) and did not (non-participants) enroll in GET-WEL. Interviews were coded and analyzed via comparative thematic analysis. Results: Of the 24 interviewees, 9 (8 White, 1 Black) were GET-WEL participants, and 15 (8 White, 6 Black, 1 Asian) were non-participants. There were no thematic differences between Black and White BCS. Most non-participants lacked awareness that the Program was recruiting. Program accountability, session flexibility, and pre-existing exercise routines emerged as facilitators while inability to identify enjoyable physical activities, difficulty accessing healthy foods, and competing work/life priorities emerged as barriers. Conclusion: Our results suggest that enhancing Program awareness and outreach may increase enrollment in minoritized BCS. Resources providing healthy foods and support to ease competing work/life priorities may help BCS maintain healthy lifestyles during and after GET-WEL. These results may help inform future large-scale GET-WEL implementation.


  • ASO Visual Abstract: Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and is Common in Patients with HER2+ Breast Cancer

    by Julia Tchou, Soumy Gottipati, Macy Goldbach, Molly Baxter, Sara Venters, Ron Balassanian, Poonam Vohra, Diego Gonzalves, Zahra Ahmad, Anupma Nayak, et al.

  • Open Access

    Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and Common Among Patients with HER2+ Breast Cancer

    by Julia Tchou, Soumy Gottipati, Macy Goldbach, Molly Baxter, Sara Venters, Ron Balassanian, Poonam Vohra, Diego Gonzalves, Zahra Ahmad, Anupma Nayak, et al.

    Background: Rates of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) for breast cancer have improved, especially among human epidermal growth factor 2-positive (HER2+) and triple-negative subtypes. The frequency and significance of biomarker profile change in residual disease are unclear. This study aimed to determine the rate of biomarker profile changes after NAC and the impact on clinical outcomes in a contemporary cohort. Methods: Upon institutional review board approval, the study identified 634 consecutive patients treated with NAC between 2010 and 2022 at two academic institutions. The study cohort was focused on patients with residual disease who underwent biomarker profile retesting. Biomarker profile change for each subtype was compared across groups using Fisher-Irwin tests. Cox Proportional Hazards Model and Kaplan-Meier plots were performed to evaluate the association of changed versus unchanged biomarker profile with event-free survival. Results: Biomarker retesting was performed for 259 (61.4 %) of 422 patients with residual disease. Biomarker profile change occurred in 18.1 % overall and was significantly higher among those with pre-NAC HER2+ disease (32.7 %, 17/52) than among those with HER2–disease (14.5 %, 30/207) (p = 0.004). Conversion of pre-NAC biomarker profiles of HR+HER2– and HR+HER2+ to triple-negative breast cancer (TNBC) post-NAC may be associated with worse event-free survival, hazard ratios of 2.23 (95 % confidence interval [CI], 0.90–5.53; p = 0.08), trending toward significance, and 36.7 (95 % CI, 2.2–610.8; p = 0.01), respectively. Conclusions: The results from one of the largest contemporary cohorts demonstrated that biomarker profile change in patients with residual disease after NAC was common. Furthermore, specific biomarker profile change in residual disease may have prognostic value. These findings strengthen the rationale for routine re-testing of biomarkers in residual disease after NAC.